Report Highlights

Epsom Salt in the U.S.: Market Overview

The U.S. Epsom salt market was valued at USD 148 million in 2024 and is structured across three streams: over-the-counter laxatives, personal-care bath salts, and agricultural magnesium amendments sold through garden centers and farm input dealers. Private manufacturers and brand owners dominate product development, retail placement, and promotion, with Church & Dwight's Dr. Teal's and Epsoma capturing much of the branded shelf space. Government participation is indirect, operating through FDA drug and cosmetic frameworks and through state fertilizer registration rather than direct procurement or public ownership of production.

Structurally, the market is concentrated at the supply end and fragmented at retail. A small number of mineral and chemical producers supply magnesium sulfate to packers, who repack it under national and private-label brands sold through mass retail and e-commerce. Demand growth since 2019 has come from wellness and home-care channels, driven by brand marketing rather than by any federal program targeting Epsom salt directly. Government has therefore set the product-safety obligations, while private brands have led growth in volume and shelf presence.

Policy-Driven Growth in U.S. Epsom Salt

Three mechanisms shape demand. First, the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), enacted as Division FF, Title III of the Consolidated Appropriations Act, 2023 (P.L. 117-328), requires facility registration, product listing, and safety substantiation for bath salts marketed as cosmetics, administered by the FDA. Compliance raises entry costs for small suppliers and transfers share toward registered national brands, which then expand product lines and retail facings.

Second, the Environmental Quality Incentives Program (EQIP), authorized under the Agriculture Improvement Act of 2018 (P.L. 115-334) and administered by USDA's Natural Resources Conservation Service, provides cost-share for nutrient management under Conservation Practice Standard 590, covering magnesium amendments on deficient soils. Growers in Coastal Plain soils therefore buy more amendment, lifting agricultural tonnage. Third, FDA's OTC monograph system, funded through user fees under the CARES Act (P.L. 116-136), keeps laxative Epsom salt on shelves under standardized Drug Facts labeling, sustaining stable OTC volumes.

Regulatory Barriers and Compliance Costs

Drug-grade barriers are the most demanding. Epsom salt sold as a laxative must comply with current Good Manufacturing Practice under 21 CFR Parts 210 and 211, with FDA inspections extending to contract packing facilities. A non-compliant facility faces warning letters and shipment holds, and remediation typically costs several hundred thousand dollars plus six to twelve months of delay before revalidated production resumes.

Agricultural and state-level barriers are administrative. Fertilizer and soil amendment labels, including magnesium guarantees, must be registered annually with state departments of agriculture, for example under Chapter 63 of the Texas Agriculture Code, with per-ton inspection fees and fixed renewal cycles. MoCRA adds serious adverse event reporting within 15 business days and facility registration obligations, creating recurring compliance costs for small bath-salt brands.

Policy-Created Opportunities in U.S. Epsom Salt

MoCRA creates a contract-manufacturing opportunity. Registered facilities able to document safety substantiation and cosmetic good manufacturing controls can win volume from brands that lack in-house compliance infrastructure. Contract packers with registered status and microbial testing capability will capture most incremental private-label bath salt volume through 2028.

EQIP-supported soil amendments and pharmaceutical injectables represent the second and third openings. Growers on Coastal Plain and Florida sandy soils can use EQIP cost-share to buy magnesium sulfate, and suppliers delivering NRCS-eligible product through state conservation channels gain direct access to subsidized demand. Hospitals purchasing USP magnesium sulfate injection under FDA-approved labeling form a stable, low-price-sensitivity demand base.

Market at a Glance

Leading Market Participants

• Epsoma
• Morton Salt
• Church & Dwight
• Jost Chemical
• Hawkins Inc.
• Spectrum Chemical Manufacturing
• MilliporeSigma
• Thermo Fisher Scientific
• VWR International
• Compass Minerals

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), as amended by MoCRA, with the Food and Drug Administration as lead regulator. The FDA's Center for Drug Evaluation and Research oversees OTC laxative products, while its Human Foods Program oversees food-grade magnesium sulfate under GRAS status in 21 CFR 184.1443. Key requirements include MoCRA facility registration, product listing, safety substantiation, and 15-business-day serious adverse event reporting. Upcoming changes include FDA's MoCRA implementing rules on cosmetic safety substantiation and labeling, with final rules projected for 2026.

Compared with regional peers, the U.S. framework is more permissive on pre-market review but more punitive on post-market enforcement. The EU Cosmetics Regulation (EC) No 1223/2009 requires a Responsible Person, a Cosmetic Product Safety Report, and CPNP notification before products reach market. Canada requires cosmetic notification to Health Canada, and Mexico's COFEPRIS applies equivalent notification. The U.S. system instead shifts liability to mandatory reporting, recalls, and FDA inspection.

Long-Term Policy Outlook for U.S. Epsom Salt

By 2032, the FDA will finalize MoCRA safety substantiation and labeling rules, tightening documentation for bath-salt brands and favoring registered manufacturers with in-house toxicology review. Market consolidation will follow as sub-scale packers exit, lifting branded share held by Church & Dwight's Dr. Teal's and Epsoma. MoCRA enforcement capacity will expand as FDA staffing for cosmetic inspections grows.

Agricultural policy will be set by the successor to the Agriculture Improvement Act of 2018, which governs EQIP funding levels through the forecast period. Stable or rising EQIP allocations extend cost-share access for magnesium amendments on Southeastern and Coastal Plain soils, supporting steady tonnage growth at a 4.7% CAGR. Pharmaceutical magnesium sulfate supply remains tied to FDA ANDA approvals and USP compliance, keeping hospital demand stable.